Research Progress on the Heterogeneity of Tumor Immune Microenvironment and Mechanisms of Resistance to Immune Checkpoint
Sci Online · 2026
DOI: 10.66106/soabcv.20260201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sci Online, 2026. Verfasst von Gang Liu. Die Arbeit nennt 1 Literaturangaben.
Abstract (Originalsprache)
The use of immune checkpoint therapies like PD-1/PD-L1 and CTLA-4 antibodies has helped control or even cure many cancer patients. However, only a few patients get lasting effects, and primary and acquired resistance remain major issues. The tumor immune microenvironment (TIME), which includes tumor cells, immune cells, stromal cells, blood vessels, and various inflammatory mediators and metabolic products, is diverse and affects how tumors respond to immunotherapy. This review covers the cancer-immunity cycle, key cellular networks in TIME, reasons for immune checkpoint resistance, potential biomarkers, and various strategies to improve treatment outcomes. It especially emphasizes the presence or absence of CD8+ T cells, tumor-associated macrophages,myeloid-derived suppressor cells, regulatory T cells, and the spatial distribution of cells in relation to therapy effectiveness,and it also looks ahead to the development of multi-omics and personalized immunotherapy.
Zitieren
APA
Liu, G. (2026). Research Progress on the Heterogeneity of Tumor Immune Microenvironment and Mechanisms of Resistance to Immune Checkpoint. Sci Online. https://doi.org/10.66106/soabcv.20260201
Vancouver
Liu G. Research Progress on the Heterogeneity of Tumor Immune Microenvironment and Mechanisms of Resistance to Immune Checkpoint. Sci Online. 2026. doi:10.66106/soabcv.20260201
BibTeX
@article{Liu2026,
author = {Liu, Gang},
title = {Research Progress on the Heterogeneity of Tumor Immune Microenvironment and Mechanisms of Resistance to Immune Checkpoint},
journal = {Sci Online},
year = {2026},
doi = {10.66106/soabcv.20260201}
}
EUVIMED